Main content

Freshfields advises Advent and Zentiva on Zentiva’s acquisition of Alvogen’s CEE business


Freshfields Bruckhaus Deringer LLP (‘Freshfields’) has advised global private equity investor Advent International and its European medicines producer Zentiva on Zentiva’s acquisition of the Central and Eastern European business of Alvogen, the global pharmaceutical company.

Alvogen CEE markets over 200 generic and over-the-counter products across multiple therapeutic areas, consisting of highly recognised brands like Lactacyd, Persen, EuBiotic and many more with leading market positions in 14 key markets across CEE including; Russia, Romania, Bulgaria, Hungary, Poland and Balkan markets.

This transaction brings together two leading branded generics and OTC businesses in the CEE region, with complementary strengths, product portfolios, geographical footprints and cultures. The transaction is expected to close in the first quarter of 2020, subject to customary approvals.

The multi-jurisdictional Freshfields team was led by James Scott and Vincent Bergin in London. They were supported by healthcare and carve-out experts Jochen Dieselhorst and Lutz Dralle, tax partner Helen Lethaby and antitrust partner Alan Ryan.

ENDS

Notes for Editors

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer LLP is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on ground-breaking and business-critical mandates. Our 2,800 plus lawyers deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multi-national expertise and business know-how means our clients rely on us when it matters most.

The Freshfields team was led by: